SCHEMBL2164245

SCHEMBL2164245

Fc1ccc(Nc2nnnc3ccccc23)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.70
KMT2A Q03164 5/20 0.70
TDP1 Q9NUW8 2/20 0.70
RAB9A P51151 2/20 0.70
CTDSP1 Q9GZU7 1/20 0.70
ABCG2 Q9UNQ0 2/20 0.60
EGFR P00533 1/20 0.56
KDR P35968 1/20 0.56
LMNA P02545 4/20 0.51
CYP1A2 P05177 3/20 0.51
HSD17B10 Q99714 3/20 0.51
ALDH1A1 P00352 3/20 0.51
CYP3A4 P08684 2/20 0.51
KDM4E B2RXH2 2/20 0.51
HPGD P15428 2/20 0.51
USP2 O75604 2/20 0.51
MAPT P10636 2/20 0.51
CYP2C19 P33261 2/20 0.51
CLK4 Q9HAZ1 1/20 0.51
TSHR P16473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3757318 0.86 MEN1 (0.69) MEN1KMT2ATDP1RAB9ACTDSP1
SCHEMBL2163688 0.85 MEN1 (0.60) MEN1KMT2ATDP1RAB9ACTDSP1
SCHEMBL3757886 0.85 MEN1 (0.68) MEN1KMT2ATDP1RAB9ACTDSP1
SCHEMBL2163410 0.79 RAB9A (0.68) MEN1KMT2ATDP1RAB9ACTDSP1
SCHEMBL2164231 0.79 EGFR (0.67) MEN1KMT2ATDP1RAB9ACTDSP1
SCHEMBL2164699 0.79 MEN1 (0.57) MEN1KMT2ATDP1RAB9ACTDSP1
SCHEMBL12401609 0.79 MEN1 (0.57) MEN1KMT2ATDP1RAB9ACTDSP1
SCHEMBL3765577 0.78 MAPT (0.64) MEN1KMT2ATDP1RAB9ACTDSP1
SCHEMBL2163667 0.77 MEN1 (0.65) MEN1KMT2ATDP1RAB9ACTDSP1
SCHEMBL5569041 0.77 EGFR (0.75) KMT2ARAB9AABCG2EGFRKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US claimed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP claimed
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US disclosed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US disclosed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF KDR, FLT1, FLT4 MEN1 2848/4885KMT2A 2444/4885TDP1 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.